prof. dr. F. (Femke) van Wijk

prof. dr. F. (Femke) van Wijk

Full Professor
prof. dr. F. (Femke) van Wijk
  • Center for Translational Immunology (CTI) Research



Dr. van Wijk obtained her PhD on mechanisms of oral tolerance and allergic sensitization to peanut at the Utrecht University in 2006. After her first postdoctoral training in human immunology in the lab of Prof. B. Prakken at the UMCU she obtained a KNAW fellowship for a 2-year postdoc in the lab of Prof. H. Cheroutre in the La Jolla Institute for Immunology in La Jolla (USA) to work on tissue T cell adaptation . After being awarded a VENI personal fellowship, she moved to the UMCU to start her own research group. For her research on how antigen presenting cells sabotage T cell regulation in local inflammation van Wijk was awarded a prestigious ZonMw VIDI career development grant (2014), and in 2021 she received a ZonMw VICI grant for her work on naïve T cell imprinting and immune development. Her research program aims to elucidate tissue T cell responses in health and inflammation and to translate these insights into tools for (pre-clinical) disease monitoring and therapeutic targeting in chronic inflammatory diseases.  She takes a disease- and age-overarching approach to decipher common and specific pathogenic processes underlying different inflammatory conditions and one of her specific interests is early imprinting of disease. Diseases her group is working on include atopic dermatitis, inflammatory bowel disease, juvenile idiopathic arthritis, juvenile dermatomyositis and immune toxicity following immune therapy in cancer.

 Dr. van Wijk is the author of >100 publications in leading peer-reviewed journals and has extensive experience with national and international scientific advisory committees (NWO off-road program, samenwerkende gezondheidsfondsen PPS Immunology consortia, Sanofi type 2 innovation grant, EU Horizon 2020 REA-FET-OPEN and COFUND). She is participating in several international networks including T_CELL_CONNECT_EUROPE, Eureka Institute for Translational Medicine, and Understanding Childhood Arthritis Worldwide Network that are aimed at (international) exchanges and training of young scientists, knowledge sharing, and enhancing reproducibility of human data. In 2017 Dr. van Wijk received the PhD supervisor of the year award by the Utrecht University Graduate School of Life Sciences.

Dr. van Wijk is also manager research for the division paediatrics at the UMCU , and scientific director FOCIS (federation of clinical immunology societies) center of excellence.

Side Activities

2016-2017 Scientific review panel member “off-road” grant program, The Netherlands Organization of Scientific Research (NWO)

2017 Member of international advisory board new Allergy and Inflammation center Guangzhou Medical University, China (honorary)

2019 Scientific review panel member Sanofi Genzyme European innovation grant

2019 Scientific review panel member, Ørsted COFUND programme (co-funded by Marie Skłodowska-Curie Actions under H2020 )/ Technical University Denmark/ Denmark

2020 Scientific review panel member  H2020 FET-Open Challenging Current Thinking, the Enhanced European Innovation Council (EIC)

2021 Scientific review panel member The Research Foundation – Flanders (FWO)  TBM2021, Belgium

2018-current Member Utrecht Life Sciences Program Board, domain One Health (honorary)

2020 - current Scientific director FOCIS (federation of clinical immunology societies) center of excellence UMC Utrecht. (honorary)

2021-current Member scientific advisory committee "Samenwerkende Gezondheidsfondsen PPS Immunologie Consortia" (honorary)

2017-current Occasional consultant/speaker for Takeda, Johnson&Johnson, Janssen, Sanofi, Regeneron, VC lspvc 



Fellowship and Awards

ZonMw VICI (2021)

PhD Supervisor (co-promotor) of the year 2017, Graduate School of Life Sciences

Stimulerings Associate Professorship UMCU (2015)

ZonMw VIDI (2014)

ZonMw Veni (2010)

KNAW fellowship Ter Meulen Fund (2007)



Research Output (123)

Highly multiplexed spatial analysis identifies tissue-resident memory T cells as drivers of ulcerative and immune checkpoint inhibitor colitis

van Eijs Mick J.M., ter Linde José J.M., Baars Matthijs J.D., Amini Mojtaba, Laclé Miangela M., Brand Eelco C., Delemarre Eveline M., Drylewicz Julia, Nierkens Stefan, Verheijden Rik J., Oldenburg Bas, Vercoulen Yvonne, Suijkerbuijk Karijn P.M., van Wijk Femke 20 Oct 2023, In: iScience. 26

Toxicity-specific peripheral blood T and B cell dynamics in anti-PD-1 and combined immune checkpoint inhibition

van Eijs Mick J M, Verheijden Rik J, van der Wees Stefanie A, Nierkens Stefan, van Lindert Anne S R, Suijkerbuijk Karijn P M, van Wijk Femke, 4 Oct 2023, In: Cancer Immunology, Immunotherapy. 72 , p. 4049-4064 16 p.

Immunosuppression for immune-related adverse events during checkpoint inhibition:an intricate balance

Verheijden Rik J, van Eijs Mick J M, May Anne M, van Wijk Femke, Suijkerbuijk Karijn P M 12 May 2023, In: NPJ precision oncology. 7

Limited excretion of dupilumab into breastmilk:A case report

Dekkers Coco, El Amrani Mohsin, van Luin Matthijs, Bakker Daphne, Plusjé Leon, van Wijk Femke, de Bruin-Weller Marjolein 5 May 2023, In: JEADV : journal of the European Academy of Dermatology and Venereology. 37 , p. e1154-e1155

Biological Tipping Point in Patients with Atopic Dermatitis Treated with Different Dosing Intervals of Dupilumab

Dekkers Coco, van der Wal M Marlot, El Amrani Mohsin, van Luin Matthijs, Bakker Daphne S, de Bruin-Weller Marjolein, van Wijk Femke 28 Mar 2023, In: Journal of Investigative Dermatology. 143 , p. 1822-1825.e3

Dupilumab-associated ocular surface disease in atopic dermatitis patients:clinical characteristics, ophthalmic treatment response, and conjunctival goblet cell analysis

Achten Roselie, Thijs Judith, van der Wal Marlot, van Luijk Chantal, de Graaf Marlies, Bakker Daphne, de Boer Joke, van Wijk Femke, de Bruin-Weller Marjolein 19 Mar 2023, In: Allergy. 78 , p. 2266-2276 11 p.

Compartmentalization and persistence of dominant (regulatory) T cell clones indicates antigen skewing in juvenile idiopathic arthritis

Mijnheer Gerdien, Servaas Nila Hendrika, Leong Jing Yao, Boltjes Arjan, Spierings Eric, Chen Phyllis, Lai Liyun, Petrelli Alessandra, Vastert Sebastiaan, de Boer Rob J, Albani Salvatore, Pandit Aridaman, van Wijk Femke 23 Jan 2023, In: eLife. 12

Epigenetic changes in inflammatory arthritis monocytes contribute to disease and can be targeted by JAK inhibition

Peeters Janneke G C, Boltjes Arjan, Scholman Rianne C, Vervoort Stephin J, Coffer Paul J, Mokry Michal, Vastert Sebastiaan J, van Wijk Femke, van Loosdregt Jorg 10 Jan 2023, In: Rheumatology (Oxford, England). 62 , p. 2887-2897 11 p.

Bi-allelic variants in NAE1 cause intellectual disability, ischiopubic hypoplasia, stress-mediated lymphopenia and neurodegeneration

Muffels Irena J.J., Schene Imre F., Rehmann Holger, Massink Maarten P.G., van der Wal Maria M., Bauder Corinna, Labeur Martha, Armando Natalia G., Lequin Maarten H., Houben Michiel L., Giltay Jaques C., Haitjema Saskia, Huisman Albert, Vansenne Fleur, Bluvstein Judith, Pappas John, Shailee Lala V., Zarate Yuri A., Mokry Michal, van Haaften Gijs W., Nieuwenhuis Edward E.S., Refojo Damian, van Wijk Femke, Fuchs Sabine A., van Hasselt Peter M. 5 Jan 2023, In: American Journal of Human Genetics. 110 , p. 146-160 15 p.

Human TH17 cells engage gasdermin E pores to release IL-1α on NLRP3 inflammasome activation

Chao Ying-Yin, Puhach Alisa, Frieser David, Arunkumar Mahima, Lehner Laurens, Seeholzer Thomas, Garcia-Lopez Albert, van der Wal Marlot, Fibi-Smetana Silvia, Dietschmann Axel, Sommermann Thomas, Ćiković Tamara, Taher Leila, Gresnigt Mark S, Vastert Sebastiaan J, van Wijk Femke, Panagiotou Gianni, Krappmann Daniel, Groß Olaf, Zielinski Christina E 5 Jan 2023, In: Nature immunology. 24 , p. 295-308 14 p.

All research output

Thank you for your review!

Has this information helped you?

Please tell us why, so that we can improve our website.

Working at UMC Utrecht





Practical uses cookies

This website uses cookies This website displays videos from, among others, YouTube. Such parties place cookies (third-party cookies). If you do not want these cookies, you can indicate that here. We also place cookies ourselves to improve our site.

Read more about the cookie policy

Agree No, rather not